SCHOTT Pharma Aktie
WKN DE: A3ENQ5 / ISIN: DE000A3ENQ51
|
04.12.2025 18:53:34
|
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance
|
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance
Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as of December 3, 2025) of 8.2% growth at constant currencies and an EBITDA margin of 28.8%. Further, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%. Preliminary results for fiscal year 2025 are in line with market expectations and will be published in a press release later today. The full set of results for fiscal 2025 will be published on December 11, 2025, at 07:00 a.m. CET. End of Inside Information
04-Dec-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2240736 |
| End of Announcement | EQS News Service |
|
|
2240736 04-Dec-2025 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu SCHOTT Pharmamehr Nachrichten
|
12:26 |
Pluszeichen in Frankfurt: SDAX am Mittag in Grün (finanzen.at) | |
|
11:11 |
ANALYSE-FLASH: UBS senkt Ziel für Schott Pharma auf 24,70 Euro - 'Buy' (dpa-AFX) | |
|
11:11 |
ANALYSE-FLASH: RBC belässt Schott Pharma auf 'Sector Perform' - Ziel 21,50 Euro (dpa-AFX) | |
|
10:04 |
AKTIE IM FOKUS 2: Schott Pharma auf Rekordtief nach schwachen Zielvorgaben (dpa-AFX) | |
|
09:29 |
SDAX aktuell: SDAX startet im Plus (finanzen.at) | |
|
08:44 |
AKTIE IM FOKUS: Schott Pharma droht Rekordtief nach schwachen Zielvorgaben (dpa-AFX) | |
|
07:54 |
WDH/Träge Glasspritzen-Nachfrage: Schott Pharma blickt verhalten auf 2026 (dpa-AFX) |
Analysen zu SCHOTT Pharmamehr Analysen
| 12:08 | SCHOTT Pharma Kaufen | DZ BANK | |
| 08:12 | SCHOTT Pharma Buy | UBS AG | |
| 08:04 | SCHOTT Pharma Sector Perform | RBC Capital Markets | |
| 04.12.25 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
| 04.12.25 | SCHOTT Pharma Overweight | Barclays Capital |
Aktien in diesem Artikel
| SCHOTT Pharma | 17,04 | -4,27% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.